NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Abstract

Our <i>in vivo</i> modeling establishes NRF2 activation as a critical oncogenic driver, cooperating with <i>STK11</i> loss and <i>KRAS</i> activation to promote aggressive lung adenocarcinoma. In patients, oncogenic events alter the tumor immune contexture, possibly having an impact on treatment responses. Importantly, patients with NRF2-activated nonsquamous or squamous tumors have poor prognosis and show limited response to anti-PD-L1 treatment.